NEVVI Medicare utilization intelligence
or

← back

Provider profile

ACKERMAN, COURTNEY M.D.

Hematology-Oncology · NPI 1790919744 · SILVER SPRING, MD

1
Groups
63
Codes · 2024
128,301
Disclosed services

ACKERMAN, COURTNEY is a Hematology-Oncology in SILVER SPRING, MD, a member of 1 medical group, who billed 63 distinct codes to Medicare Part B in 2024.

Groups: MARYLAND ONCOLOGY HEMATOLOGY PA (LAUREL, MD)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

128,301
disclosed services
63
codes billed to Medicare Part B
Prior year · CY2023 159,951 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1439 Injection, ferric carboxymaltose, 1 mg
J0897 Injection, denosumab, 1 mg
J1756 Injection, iron sucrose, 1 mg
J0185 Injection, aprepitant, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9271 Injection, pembrolizumab, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1437 Injection, ferric derisomaltose, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J2469 Injection, palonosetron hcl, 25 mcg
88185 Flow cytometry technique for dna or cell analysis, each additional marker
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J1626 Injection, granisetron hydrochloride, 100 mcg
J9045 Injection, carboplatin, 50 mg
96372 Injection of drug or substance under skin or into muscle
82784 Gammaglobulin (immune system protein) measurement
96375 Injection of additional new drug or substance into vein
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96413 Administration of chemotherapy into vein, 1 hour or less
J2405 Injection, ondansetron hydrochloride, per 1 mg
82728 Ferritin (blood protein) level
83550 Iron binding capacity
83540 Iron level
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
36415 Insertion of needle into vein for collection of blood sample
96417 Administration of additional new drug or substance into vein, 1 hour or less
83520 Measurement of substance using immunoassay technique
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
82378 Carcinoembryonic antigen (cea) protein level
J7030 Infusion, normal saline solution , 1000 cc
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J3490 Unclassified drugs
83615 Lactate dehydrogenase (enzyme) level
96360 Infusion into a vein for hydration, 31-60 minutes
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96361 Infusion into a vein for hydration, each additional hour
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
83735 Magnesium level
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J7050 Infusion, normal saline solution, 250 cc
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
83010 Haptoglobin (serum protein) level
96374 Injection of drug or substance into vein
86140 Measurement c-reactive protein for detection of infection or inflammation
85651 Red blood cell sedimentation rate, to detect inflammation, non-automated
88184 Flow cytometry technique for dna or cell analysis, first marker
84550 Uric acid level, blood
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
38222 Biopsy and aspiration of bone marrow sample for diagnosis

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.